A call was announced today for researchers to express their interest in participating in the new EQ-5D-5L valuation study for the UK. Researchers may broadly participate in the study in three ways: as the principal investigator, a site investigator or as a member of the Steering Group.
The new EQ-5D-5L valuation study will be funded by the EuroQol Research Foundation with ongoing advisory input from NICE, the Department of Health and Social Care and NHS England. It will be overseen by a Steering Group that will include representatives from EuroQol and the UK government advisory organisations, plus experts in health-state valuation studies or valuation-data modelling. The study will be run in accordance with the latest version of the international standard EuroQol valuation study protocol (EQ-VT), which has now been used in 20 EQ-5D-5L valuation studies around the World. The EuroQol EQ-VT support team will assist the study team throughout the project. Data collection is expected to begin in late 2020.
The application form and more detailed information about the roles, study requirements and governance arrangements for new UK valuation study, can be viewed on the EuroQol website . This initiative has also been announced on the NICE website . The deadline for applications is 4th March 2020.
NICE’s position on EQ-5D-5L: the current position in the UK regarding the use of the EQ-5D-5L for companies, academic groups, and others preparing evidence submissions for NICE can be viewed on their website.
About valuation studies: The new valuation study will provide a UK value set for the EQ-5D-5L. The value set will provide values (weights) for EQ-5D-5L health state descriptions according to the preferences of the UK general population. These are used in the calculation of quality adjusted life years (QALYs) that inform economic evaluations of healthcare interventions.
About EuroQol: The EuroQol Group is committed to supporting scientific endeavours that further the measurement and valuation of health and advance the use of measures like the EQ-5D-5L to benefit patients and inform decision makers. For further information please do not hesitate to contact us.